<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742933</url>
  </required_header>
  <id_info>
    <org_study_id>VUmc_2020-4973</org_study_id>
    <nct_id>NCT04742933</nct_id>
  </id_info>
  <brief_title>CCTA and Dynamic CT Perfusion for the Diagnosis of Myocardial Ischemia in Patients With Coronary Stents</brief_title>
  <acronym>PACIFIC-III</acronym>
  <official_title>A Head-to-Head Prospective Comparison of Diagnostic Accuracy of CCTA and Dynamic CT Perfusion in Patients With Prior PCI for the Diagnosis of Myocardial Ischemia as Defined by Invasive Flow and Pressure Indices - PACIFIC-III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single centre prospective trial in which patients with a prior PCI for stable CAD who are&#xD;
      referred for invasive angiography will undergo state-of-the art CCTA and dynamic CT&#xD;
      perfusion. Subsequently invasive FFR and iFR measurements will be routinely performed in each&#xD;
      coronary vessel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Recent development in computed tomography (CT) hardware have fulfilled the&#xD;
      prerequisites for clinical CT myocardial perfusion imaging (CTP). Cardiac CT, has by means of&#xD;
      coronary computed tomography angiography (CCTA) and novel techniques such as CTP the unique&#xD;
      ability to provide information on both the anatomical and functional severity of coronary&#xD;
      artery disease (CAD). However, diagnostic performance of these novel techniques when&#xD;
      referenced by the clinical diagnostic standard, invasive fractional flow reserve (FFR)&#xD;
      measurements, has scarcely been investigated in patients with a prior PCI.&#xD;
&#xD;
      Objective: To determine the diagnostic performance of CCTA and dynamic CTP for the diagnosis&#xD;
      of myocardial ischemia using invasive coronary indices as the reference standard.&#xD;
&#xD;
      Study design: The study is a single-center prospective comparative trial in which all&#xD;
      patients will undergo CCTA and dynamic CTP before invasive coronary angiography (ICA) in&#xD;
      conjunction with invasive flow/pressure measurements.&#xD;
&#xD;
      Study population: Patients referred for a diagnostic ICA with a prior of PCI for stable CAD&#xD;
      will be evaluated for inclusion in the study.&#xD;
&#xD;
      Main study parameters/endpoints: Hemodynamic significant CAD as defined by an FFR ≤0.80 / iFR&#xD;
      &lt; 0.90. Sensitivity, specificity, negative predictive value, positive predictive value and&#xD;
      accuracy will be assessed for CCTA and dynamic CTP. In addition, this study will assess the&#xD;
      prognostic value of CCTA and dynamic CTP in patients with a prior cardiac revascularization.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: A two day protocol will be completed after referral ensuring the diagnostic&#xD;
      work-up of patients is not delayed. On day 1 patients will undergo CCTA and CTP. Then, on day&#xD;
      2, irrespective of CT results, patients will undergo ICA with invasive pressure measurements.&#xD;
      The risks of CT are considered to be low. Patients are referred for a clinically indicated&#xD;
      ICA and as such risks of the ICA are not deemed study-related. Future patients might benefit&#xD;
      from the present study as combined anatomical information (CCTA) and functional information&#xD;
      (dynamic CTP) might lead to a more judicious referral for ICA which leads to a reduction of&#xD;
      exposure to invasive procedures such as ICA in combination with invasive pressure&#xD;
      measurements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 25, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificity of Dynamic CT-perfusion and CCTA for CAD</measure>
    <time_frame>3 years</time_frame>
    <description>FFR will be used as a reference standard, the primary endpoint is an abnormal FFR =&lt; 0.80. Diagnostic study using FFR as endpoun</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events, cardiac death or repeat revascularization</measure>
    <time_frame>3 years</time_frame>
    <description>The secondary endpoint is to assess the prognostic value of CT in patients with a prior history of PCI</description>
  </secondary_outcome>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Coronary Artery Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>There is no intervention in this observational trial</intervention_name>
    <description>There is no intervention in this observational trial</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      4 blood samples (21.5 Ml) for the PACIFIC 3 Biobank&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred for a diagnostic ICA with a prior of PCI for stable CAD will be evaluated&#xD;
        for inclusion in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of PCI for stable CAD&#xD;
&#xD;
          -  Referred for a diagnostic ICA.&#xD;
&#xD;
          -  Age above 30 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe COPD or chronic asthma&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Renal failure (eGFR &lt;30 mL/min)&#xD;
&#xD;
          -  Use of sildenafil (Viagra) or dipyramidol (Persantin) that cannot be terminated&#xD;
&#xD;
          -  Contra-indications for β-blockers&#xD;
&#xD;
          -  Allergic reaction to iodized contrast&#xD;
&#xD;
          -  Concurrent or prior (within last 30 days) participation in other research studies&#xD;
             using investigational drugs&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Significant co-morbidities&#xD;
&#xD;
          -  Atrial fibrillation, second or third degree atrioventricular block&#xD;
&#xD;
          -  Tachycardia&#xD;
&#xD;
          -  Acute myocardial infarction&#xD;
&#xD;
          -  History of CABG&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  Cardiomyopathies&#xD;
&#xD;
          -  Previous radiation exposure in the diagnostic work-up&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Indispensable follow-up with (serial) CT scans for non-cardiac related condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Knaapen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ibrahim Danad, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruurt A Jukema, MD</last_name>
    <phone>+312-4443262</phone>
    <email>r.jukema@amsterdamumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amsterdam UMC, location VUMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruurt Jukema, MD</last_name>
      <phone>+31204443262</phone>
      <email>r.jukema@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>Ibrahim Danad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pieter G Raijmakers, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cornelis van Kuijk, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Chamuleau, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Ibrahim Danad, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Computed tomography angiography</keyword>
  <keyword>Computed tomography Perfusion</keyword>
  <keyword>FFR</keyword>
  <keyword>Prior revascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

